Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 8/16/18 → 8/24/25 |
Funding
- Bristol Myers Squibb Company: $164,249.00
18-LUN-106-BMS (CA209816) Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
- Villano, PhD, John (PI)